Pershing Capital's 8.3% stake and actions to control ADP's board should attract speculative buying interest.
Reports that billionaire Bill Ackman might be accumulating a stake in Automatic Data Processing have caused shares of the company to rise quickly.
The multinational company saw its stock decline by nearly 2% at market open.
Valeant might be the biggest victim of the FDA’s bid to lower drug prices by boosting generic competition.
Bill Ackman may reap the benefits if Blackstone Group buys half of Platform Specialty Products.
The hedge fund manager John Paulson joins the pharmaceutical company's board after losing almost $2 billion on a bad bet on Valeant stock.
Andrew Left of Citron Research successfully shorted Valeant and other companies. Now he sees Nvidia as the latest target.
Valeant Pharmaceuticals is setting off buy signals after Bill Ackman's Pershing Capital pulled up stakes and took a massive loss. (VRX)
Apart from its notorious dumping of Valeant stock, the firm cut its holdings in snack maker Mondelez and Air Products and Chemicals.
Is it too little, too late for Valeant investors?